Browsing Tag
Pharma Industry Awards UK
1 post
Avacta wins pre|CISION R&D award, but AVA6103’s H1 2027 efficacy test matters more
Avacta Group plc has moved AVA6103 into its fourth Phase 1 dose level after early human data supported the intended controlled-release mechanism of its pre|CISION platform. The next valuation test is shifting from pharmacokinetic validation to whether higher payload exposure produces meaningful antitumour activity.